Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-093 in moderate to severe chronic plaque psoriasis
NCT00147329Phase 2Completed
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Sep 2005
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human alpha-fetoprotein in plaque psoriasis, sponsored by Merrimack Pharmaceuticals. Started Sep 2005; status: completed.
02
Drugs
recombinant human alpha-fetoprotein
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00147329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00147329.